http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_367ff53d0cc61a1655f1603605618944
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Wolf |
| name | Jürgen Wolf |
| given-name | Jürgen |
| organization-name | Authors' Affiliations: 1Department of Translational Genomics, University of Cologne; 2Max-Planck-Institute for Neurological Research; Institutes of 3Pathology and 4Virology, University of Cologne;5Department I of Internal Medicine and Center for Integrated Oncology, University Hospital of Cologne; 6Blackfield AG, Cologne; 7Technical University Dortmund, Dortmund, Germany; 8Medical Oncology and 9Institute of Pathology, Cantonal Hospital, Luzern; 10Novartis Pharma AG, Basel, Switzerland; and 11Division of Natural Products Chemistry, CSIR–Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India 2Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany. Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d’Oncologia, Barcelona; Manuel Hidalgo, START Madrid; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy,... 4Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany. 6Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. From the Center for Integrated Oncology Köln Bonn; Clinic for Nuclear Medicine, University Hospital of Cologne; Lung Clinic Merheim, Hospital of Cologne; Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne; Evangelical Hospital Kalk; Hospital Holweide; Max-Planck Institute for Neurological Research, Cologne; Institute of Pathology, University Hospital Bonn; Johanniter Hospital Bonn, Bonn; European Institute of Molecular Imaging, University of Münster, Germany; and Vrije... Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany. From the German Hodgkin’s Lymphoma Study Group, Cologne, Germany. 2Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.; 9Department I of Internal Medicine and Centre of Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany. Authors' Affiliations: 1Department I of Internal Medicine, 2Institute of Medical Statistics, Informatics and Epidemiology, 3Department of Dermatology and Venerology, 4Department of Orthopaedic and Trauma Surgery, Center for Integrated Oncology, University Hospital Cologne; 5Max Planck Institute for Neurological Research with Klaus-Joachim-Zülch Laboratories of the Max Planck Society and the Medical Faculty of the University of Cologne; 6Institute for Transfusion Medicine, University of Cologne; 7Lung Clinic Merheim, Cologne; 8LIMES (Life and Medical Sciences Bonn), Laboratory for Genomics and Immunoregulation, University of Bonn, Bonn; and 9IBE Department of Epidemiology, University of Munich, Munich, Germany Center for Integrated Oncology Cologne, University Hospital Cologne Kerpener Straße 62 Cologne 50937 Germany; Center for Integrated Oncology Bonn, University Hospital Bonn Sigmund‐Freud Straße 25 53105 Bonn Germany; Lung Cancer Group Cologne University Hospital Cologne Kerpener Straße 62 Cologne 50937 Germany; Clinic for Internal Medicine I, University Hospital Cologne Kerpener Straße 62 Cologne 50937 Germany Department of Internal Medicine, University Clinic Cologne 2 2 Joseph-Stelzmannstr. 9, 50924 Köln, Germany Network Genomic Medicine Cologne Germany; Lung Cancer Group Cologne Department I of Internal Medicine University Hospital of Cologne Cologne Germany; Center for Integrated Oncology Koeln Bonn Cologne Germany 1st Department of Internal Medicine University of Cologne Cologne Germany 2Department I of Internal Medicine, Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Cologne, Germany. From the Canton Hospital, Basel, Switzerland; Radiotherapy and Internal Medicine Departments, Münich University, Münich; Biometry, Radiotherapy, and Internal Medicine Departments, Cologne University, Cologne; Munster University, Munster; Moabit Hospital, Berlin; Innsbruck University, Innsbruck; Klinikum Passau, Passau; and Pathology Department, Hannover Medical School, Hannover, Germany. Dep. I of Internal Medicine I, Center for Integrated Oncology, University Hospital of Cologne, D-50924 Cologne, Germany. All authors: University Hospital of Cologne; Martin L. Sos, University of Cologne, Cologne, Germany. Laboratory of Translational Cancer Genomics, Center of Integrated Oncology Köln-Bonn, University of Cologne, 50924 Cologne, Germany.; Department I of Internal Medicine and Center of Integrated Oncology Köln-Bonn, University of Cologne, 50924 Cologne, Germany. Department I of Internal Medicine Center for Integrated Oncology Cologne University Hospital of Cologne Cologne Germany Innere Medizin I, Uniklinik Köln, Köln Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Lung Cancer Group University of Cologne Cologne Germany Department I of Internal Medicine and Center for Integrated Oncology Köln‐Bonn University of Cologne Cologne Germany 14Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany. Department of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital Cologne, Cologne, 50931 Cologne, Germany. From the University of Texas M.D. Anderson Cancer Center, Houston (F.S.), and U.S. Oncology Research, the Woodlands (A. Spira) — both in Texas; Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (B.T.L.) and Thoracic Medical Oncology, Perlmutter Cancer Center, New York University (V.V.), New York, and Roswell Park Cancer Institute, Buffalo (G.K.D.) — all in New York; the Queen Elizabeth Hospital and University of Adelaide, Woodville, SA, Australia (T.J.P.); Sarah Cannon Research Institute... Noopur Raje and Andrew J. Yee, Massachusetts General Hospital, Boston, MA; Ian Chau and Martin Kaiser, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; David M. Hyman, Heather Landau, and Jose Baselga, Memorial Sloan Kettering Cancer Center, New York; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Vincent Ribrag, Jean-Marie Michot, and Antoine Hollebecque, Institut Gustave Roussy, Villejuif; Jean-Yves Blay, Centre Leon-Berard, Lyon, France; Josep Tabernero and Elena Elez, Vall d’Hebron... All authors: Center of Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany. University Hospital of Cologne, Cologne, Germany Medical Clinic I University Hospital Cologne Cologne Germany Authors' Affiliations: 1Department of Translational Genomics; 2Department I of Internal Medicine; 3Laboratory of Translational Cancer Genomics; 4Network Genomic Medicine, University Hospital Cologne, Center of Integrated Oncology Cologne–Bonn; 5Center for Molecular Medicine Cologne (CMMC); 6Cologne Center for Genomics (CCG); 7Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); 8Department of Pathology, University Hospital Medical Center, University of Cologne; 9Blackfield AG; 10Max Planck Institute for Neurological Research; 11Thoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH; 12Institute of Human Genetics, Cologne; 13Computational Molecular Biology Department, Max Planck Institute for Molecular Genetics, Berlin; 14Department of Prostate Cancer Research, Institute of Pathology; 15Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn; 16Institute of Pathology; 17Department of Internal Medicine II, Jena Universit; Authors' Affiliations: 1Department of Translational Genomics; 2Department I of Internal Medicine; 3Laboratory of Translational Cancer Genomics; 4Network Genomic Medicine, University Hospital Cologne, Center of Integrated Oncology Cologne–Bonn; 5Center for Molecular Medicine Cologne (CMMC); 6Cologne Center for Genomics (CCG); 7Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); 8Department of Pathology, University Hospital Medical Center, University of Cologne; 9Blackfield AG; 10Max Planck Institute for Neurological Research; 11Thoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH; 12Institute of Human Genetics, Cologne; 13Computational Molecular Biology Department, Max Planck Institute for Molecular Genetics, Berlin; 14Department of Prostate Cancer Research, Institute of Pathology; 15Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn; 16Institute of Pathology; 17Department of Internal Medicine II, Jena Universit; Authors' Affiliations: 1Department of Translational Genomics; 2Department I of Internal Medicine; 3Laboratory of Translational Cancer Genomics; 4Network Genomic Medicine, University Hospital Cologne, Center of Integrated Oncology Cologne–Bonn; 5Center for Molecular Medicine Cologne (CMMC); 6Cologne Center for Genomics (CCG); 7Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); 8Department of Pathology, University Hospital Medical Center, University of Cologne; 9Blackfield AG; 10Max Planck Institute for Neurological Research; 11Thoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH; 12Institute of Human Genetics, Cologne; 13Computational Molecular Biology Department, Max Planck Institute for Molecular Genetics, Berlin; 14Department of Prostate Cancer Research, Institute of Pathology; 15Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn; 16Institute of Pathology; 17Department of Internal Medicine II, Jena Universit From the Western Hospital, Melbourne, Australia; Instituto Nacional de Cancerología, Mexico City, Mexico; National Taiwan University Hospital, Taipei, Taiwan; Meir Medical Center, Kfar Saba, Israel; Veterans Memorial Medical Center, Quezon City, Philippines; Panorama Medical Center and New Groote Schuur Hospital, Cape Town, South Africa; San Camillo-Forlanini Hospital, Rome, Italy; Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany; Christie Hospital National Health Service... 1Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.; 2Network Genomic Medicine (Lung Cancer), Cologne, Germany. Network Genomic Medicine Cologne Germany; Lung Cancer Group Cologne, Department I for Internal Medicine University Hospital of Cologne Cologne Germany; Center for Integrated Oncology Cologne Bonn Germany From the Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne and University of Cologne, Cologne (J.W.), Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg, Heidelberg (M.T.), the Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen (T.R.O.), and Hämato-Onkologie Hamburg, Hamburg (E.L.) - all in Germany; the National Hospital Organization Kyushu Cancer Center, Fukuoka (T.S.), Aichi Cancer Center, Nagoya (T.H.), the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo (M.N.), the Department of Respiratory Medicine, Okayama University Hospital, Okayama (K.O.), and the National Kyushu Cancer Center, Fukuoka (R.T.) - all in Japan; the National Cancer Center, Gyeonggi-do (J.-Y.H.), and the Department of Internal Medicine, Seoul National University Hospital, Seoul (T.-M.K.) - both in South Korea; the Hospital Clinic of Barcelona (N.R.), Translational Genomic and Targeted Therapeutics in Solid Tumors (IDIBAPS) (N.R.), and Vall d'Hebron University Hospital-Vall d'Hebron Institute of Oncology (E.F.), Barcelona; David Geffen School of Medicine at UCLA, Los Angeles (E.B.G.); the University of Groningen and University Medical Center Groningen, Groningen (H.J.M.G.), Erasmus MC Cancer Institute, Rotterdam (M.J.), and the Netherlands Cancer Institute, Amsterdam (E.F.S.) - all in the Netherlands; the National Cancer Centre Singapore, Singapore (D.S.W.T.); St. Petersburg Pavlov State Medical University, St. Petersburg, Russia (S.V.O.); University Hospital of Lyon-Sud, Lyon (P.-J.S.), and Novartis Pharma, Rueil-Malmaison (S.L.M.) - both in France; the Respiratory Oncology Unit, University Hospitals KU Leuven, Leuven, Belgium (J.V.); the Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna (M.H.); the Thoracic Oncology Division, European Institute of Oncology, IRCCS, Milan (F.M.); Novartis Pharmaceuticals, East Hanover, NJ (A.R., M.G.); Novartis Pharma, Basel, Switzerland (M.W.-L., M.A.); and Novartis Institutes for BioMedical Research, Cambridge (B.S., O.A.B., X.C.), and Massachusetts General Hospital, Boston (R.S.H.) - both in Massachusetts. From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College (A.D., E.R.) and New York University Langone Medical Center (V.V.), New York, and Roswell Park Comprehensive Cancer Center, Buffalo (G.K.D.) — all in New York; Dana–Farber Cancer Institute (G.R.O.) and Massachusetts General Hospital (J.G.), Boston; National Cancer Centre Singapore, Singapore (D.S.W.T.); the Chinese University of Hong Kong, Hong Kong, China (H.H.F.L.); Sarah Cannon Research Institute, Nashville (M.J.);... Authors' Affiliations: 1Departments of Medical Oncology and 5Biological Chemistry and Molecular Pharmacology, 18 Center for Cancer Genome Discovery, and 21Ludwig Center, Dana-Farber Cancer Institute, Boston; 4Broad Institute, Cambridge, Massachusetts; 2Max Planck Institute for Neurological Research, Klaus-Joachim-Zülch Laboratories of the Max Planck Society, and University of Köln Medical Faculty; 3Department I of Internal Medicine and Laboratory of Translational Cancer Genomics, Center for Integrated Oncology Köln-Bonn, University of Köln; 9Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, University Hospital of Cologne; 15Kliniken der Stadt Köln gGmbH, Cologne; 6Chemical Genomics Center of the Max Planck Society and 19Technical University Dortmund, Dortmund; 13Department of Hematology/Oncology, Jena University Hospital, Jena, Germany; 7Department of Obstetrics and Gynecology, Haukeland University Hospital, and 8Department of Clinical Medicine, University of Bergen, Bergen; 12Divi; Authors' Affiliations: 1Departments of Medical Oncology and 5Biological Chemistry and Molecular Pharmacology, 18 Center for Cancer Genome Discovery, and 21Ludwig Center, Dana-Farber Cancer Institute, Boston; 4Broad Institute, Cambridge, Massachusetts; 2Max Planck Institute for Neurological Research, Klaus-Joachim-Zülch Laboratories of the Max Planck Society, and University of Köln Medical Faculty; 3Department I of Internal Medicine and Laboratory of Translational Cancer Genomics, Center for Integrated Oncology Köln-Bonn, University of Köln; 9Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, University Hospital of Cologne; 15Kliniken der Stadt Köln gGmbH, Cologne; 6Chemical Genomics Center of the Max Planck Society and 19Technical University Dortmund, Dortmund; 13Department of Hematology/Oncology, Jena University Hospital, Jena, Germany; 7Department of Obstetrics and Gynecology, Haukeland University Hospital, and 8Department of Clinical Medicine, University of Bergen, Bergen; 12Divi Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Köln-Bonn, University Hospital of Cologne, Cologne, Germany 5Department of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany bDepartment of Internal Medicine I, University of Cologne, 50931 Cologne, Germany 6Department of Internal Medicine I, Center for Integrated Oncology, Cologne University Hospital, Cologne, Germany. From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut... Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany |
Incoming Links
Total number of triples: 258.